GPI 1485

01/01/2004 - "In one, patients with moderately severe Parkinson's disease showed no overall improvement in fine motor skills following 6 months of treatment by the neuroimmunophilin GPI 1485. "
01/02/2007 - "Coenzyme Q(10) and GPI-1485 may warrant further study in Parkinson disease, although the data are inconsistent. "
01/02/2007 - "To determine if future studies of coenzyme Q(10) and GPI-1485 in Parkinson disease (PD) may be warranted. "
01/02/2007 - "A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease."
01/01/2004 - "In August 2002, phase II clinical trials investigating GPI-1485 for Parkinson's disease commenced, and in November 2003, further phase II trials commenced for post-prostatectomy erectile dysfunction."

07/01/2012 - "In the present study, we evaluated the effect of GM1485 treatment on functional recovery and neurogenesis following rat stroke. "
07/01/2012 - "These data demonstrate that GM1485 administration improves neurological function and is consistent with an upregulation of endogenous neurogenesis following stroke in rats. "
07/01/2012 - "GM1485, a nonimmunosuppressive immunophilin ligand, promotes neurofunctional improvement and neural regeneration following stroke."

01/01/2004 - "In August 2002, phase II clinical trials investigating GPI-1485 for Parkinson's disease commenced, and in November 2003, further phase II trials commenced for post-prostatectomy erectile dysfunction."
01/01/2004 - "GPI-1485 is a neuroimmunophilin ligand that binds to FK-506-binding proteins and is under development by Guilford for the potential treatment of erectile dysfunction following nerve injury during prostate resection and Parkinson's disease. "

07/01/2012 - "Transient cerebral ischemia was induced in rats receiving daily GM1485 (5 mg/kg) beginning 24 hr postischemia and continuing for a total of 6 weeks. "